EX-99.1

Except for historical information, matters set forth in this presentation, including

statements regarding Sequenom’s plans, potential, opportunities, financial or other

expectations, projections, goals, objectives, milestones, strategies, market growth,

timelines, product pipeline, clinical studies, product development, and the potential

benefits of its products and products under development, are forward-looking

statements

within

the

meaning

the

“safe

harbor”

provisions

the

Private

Securities

Litigation Reform Act of 1995. These forward-looking statements are subject to risks

and uncertainties that may cause actual results to differ materially, including the risks

and uncertainties associated with Sequenom’s operating performance and financial

position, the market demand for and acceptance of Sequenom’s and Sequenom

Laboratories’

products and services, research, development and commercialization of

new

products,

reliance

upon

the

collaborative

efforts

others,

competition,

intellectual

property

rights,

government

regulation,

obtaining

maintaining

regulatory

approvals,

litigation, and other risks detailed in Sequenom’s SEC filings. These forward-looking

statements are based on current information that is likely to change, speak only as of

the

date

hereof,

and

Sequenom

undertakes

obligation

revise

update

such

statements.

Forward-looking statements

2014 Highlights

Focused leader in Noninvasive Prenatal Testing (NIPT)

Company Snapshot**

$ Millions

Revenue

Preliminary, unaudited. Cash burn excludes the proceeds and payments from the Illumina, ISIS, and CUHK transactions in 2014.

Revenue and cash burn have been adjusted to remove discontinued operations.

***

Company received an additional $6M in January 2015 related to Illumina settlement agreement bringing the total cash to approximately $100M.

NIPT Accessioned Tests

Tests, Thousands

Financials

Approximately $94M*** in ending cash

Reduced cash burn from $107M* in FY2013 to

$37M* in FY2014

Divested Bioscience business

Leader in NIPT

Market innovator and leading test provider

Illumina Settlement and Patent Pool

Agreement

Freedom to operate

Broad capabilities to practice next generation

sequencing under Illumina supply agreement

Sequenom and Illumina Settlement

Signed December 2014

Pooled intellectual property directed to NIPT

–

Settled all pending infringement disputes

–

Illumina

enforces

Patent

Pool

globally

–

Shared test fees from licensed laboratories

–

Sequenom

receive

royalty

IVD

sales

for

NIPT

kits

Sequenom

received

$50

million

cash

–

Sequenom expects to receive an additional $80M+ through 2020,

subject

potential

market

based

adjustments

Illumina gained access to Sequenom’s clinical samples

Obtained broader field of use with amended supply agreement

Parties responsible for enforcement of their own existing litigation prior to December settlement.

In Vitro Diagnostics

Sequenom received $6M in January 2015. Sequenom paid Chinese University of Hong Kong a one-time $6M payment in 2014.

From the patent pool structure based on contractual payments, pursuant to the agreement.

Global Licenses

21 organizations globally granted licenses to

the patent pool, including Sequenom

Laboratories and Verinata, January 2015

Patent Pool Content

Partnering for growth

Clarifying the NIPT IP landscape for broader access

The patent pool combines critical NIPT

patents and patent applications

–

Sequenom controlled over 225

–

Illumina controlled over 200

Numerous NIPT technologies represented

–

Methods to detect fetal DNA for prenatal

diagnosis

–

Methods to detect fetal aneuploidy

(random, targeted, length-based)

–

Methods to extract and amplify DNA

–

Others: digital PCR; whole fetal genome

sequencing; SNPs

Roles and Responsibilities

Enhancing profitability

Capturing value from the patent pool

Illumina and Sequenom collect

existing party test fee for the

Patent Pool

Illumina Responsibilities

–

License additional parties

–

Enforcement of patents globally

–

Collect test fees from new parties

Test fees distributed quarterly

between Sequenom and Illumina

NIPT Collection Pool

NIPT test fee

collection pool

Test fee payment

Test fee revenue

Licensees

SQNM

ILMN

SQNM Labs

& Verinata

Circulating cell-free DNA (ccfDNA)

Foundational technology / core expertise

Cell free fetal DNA in maternal

blood

–

Believed to be from

placental and fetally

derived cells

1,2,3

Next generation sequencing of

ccfDNA allows for accurate

identification of fetal

chromosomal abnormalities

Placental

Cells, DNA

1.Lo YM, Corbetta N, Chamberlain PF, Rai V, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997 Aug 16;350(9076):485-487.

2.Finning KM, Martin PG, Soothill PW, Avent ND.

Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD

genotyping service. Transfusion.

2002 Aug;42(8):1079-1085.

3.Bianchi DW. Circulating fetal DNA: its origin and diagnostic potential-a review. Placenta. 2004 Apr;25 Suppl A:S93-S101.

DNA

sequencing

Fetal DNA

Maternal blood

Fetal DNA

High risk pregnancies

traditionally required invasive

procedures

High requirement for medical

management and genetic

counseling

97% of invasive procedures

have normal results

Invasive testing costly and

introduces additional risk

Traditional prenatal testing

Our clinical use mirrors

criteria in validation study

Guidelines established by

ACOG

and

SMFM

perform the test on women

at increased risk for fetal

chromosomal abnormalities

Payors’

medical policies for

NIPT is currently for high

risk pregnancies

MaterniT21

PLUS test

Indications for use, >375,000 tests accessioned

1.ACOG is the American Congress of Obstetricians and Gynecologists

2.SMFM is the Society for Maternal-Fetal Medicine

NIPT Market: Large and relatively untapped

GLOBAL

PREGNANCIES

>210M

births

annually

AVERAGE RISK

3.5M

births

annually

HIGH RISK

750K births annually¹

$3B+ total

market

opportunity

worldwide

Martin JA, et al. Division of Vital Statistics. Births: Final data for 2013.

National Vital Statistics Reports.

2013;62(9). Online

http://www.cdc.gov/nchs/births.htm. Accessed Aug 7, 2014.

World Health Organization, World Health Statistics 2013.

Morgan Stanley Research, NIPT Competition Evolves, December 2, 2014.

VisibiliT

™

prenatal test

Common trisomy information mirrored

after content available in standard

serum screening

Reporting of risk score to complement

current medical and genetic counseling

practices for average risk

Sequenom the first to offer two NIPT

testing model

Launched internationally in Q4 2014

Expected US launch Q1 2015

Trisomies 21 and 18, fetal gender

Validation and performance data presented at International Society for Prenatal Diagnosis meeting in July 2014, Brisbane, Australia

First and most

comprehensive

commercial

NIPT for

high risk

pregnancies

First NIPT

utilizing

common trisomy

information

mirrored after

serum

screening

content

A carrier

screen that

analyzes the

most clinically

relevant

mutations and

variants related

to cystic

fibrosis (CF)

A noninvasive

prenatal test

that detects

fetal RhD

genotype in

RhD sensitized

mothers

A microarray

assessment of

patient sample

from a

chorionic villus

sampling

(CVS) and

amniocentesis

Sequenom test portfolio

Growing prenatal franchise

Sequenom continues to innovate NIPT

Expected product launch in 2H 2015

Reported as additional findings

2011

2012

Trisomy 21

2014

2013

Trisomy 13

Trisomy 18

Sex aneuploidies

Enhanced Sequencing Series²

Enhanced Sequencing Series II²

Additional microdeletions

2015

Noninvasive

whole genome

karyotype¹

MaterniT21

PLUS -

17 conditions, 9 whole chromosome aneuploidies, 7 microdeletions

Noninvasive karyotype

NIPT portfolio evolution

Rapidly accelerate

differentiation via our genome

wide testing capabilities

Noninvasive karyotype

–

Identifies fetal

chromosomal abnormalities

currently only seen with

invasive procedures

Expected launch in 2H 2015

Universal carrier screen opportunity

Rapidly expanding market in prenatal care

Screening for genetic disorders as part

of preconception

care

–

6.6M pregnancies in the US

annually

–

Test potential mother and/or

father

Genetic disorders are among the most

common causes of admissions to

pediatric hospitals and a significant

cause of infant mortality

Pan-ethnic screening is increasingly

been incorporated into routine

OB/GYN care

Such as Cystic Fibrosis, Spinal Muscular Atrophy, Fragile X, Alpha Thalassemia, Beta

Hemoglobinopathies and Tay-Sachs Disease

CDC, National Vital Statistics Report, Vol. 60, No 1, 2012.

HerediT

™

Universal is a carrier screen

that detects over 250 genetic diseases

–

>1700 disease causing mutations

–

Includes

all

ACMG,

ACOG

and

recommended mutations

Partnering with Recombine,

a leader in the in vitro

fertilization marketplace

Leverages commercial infrastructure

and complements existing HerediT

™

CF Carrier Screening test

Expected launch in Q1 2015

American College of Medical Genetics and Genomics; American Congress of Obstetricians and

Gynecologists; Ashkenazi Jewish Screening Recommendations by ACOG and ACMG.

HerediT

™

Universal

Sequenom enters universal carrier screening market

Sequenom enters Oncology

Building clinical foundation

Engaging key thought leaders from leading institutions:

Razelle Kurzrock, MD

Murray Professor of Medicine; Chief, Hematology & Oncology; Director, Center for Personalized Cancer

Therapy & Clinical Trials, Sr. Deputy Director UCSD Moores Cancer Center

Background of Key Opinion Leaders:

Leveraging our ccfDNA expertise

From circulating cell-free fetal DNA to circulating tumor DNA (ctDNA)

In the course of performing NIPT, Sequenom has identified over

20 significant incidental findings of confirmed maternal tumor growths¹:

Circulating cell-free DNA (ccfDNA) and next-generation sequencing

have potential broad oncology applications:

Presented in a Poster at the Association of Molecular Pathology meeting in November 2014, National Harbor, MD

Early Cancer

Detection

Treatment

Selection

Treatment

Monitoring

Relapse /

Surveillance

–

Breast cancer, colon cancer, lymphomas, etc.

Oncology program

Test type

Laboratory-developed test that

detects and profiles ctDNA

in plasma

Target population

Advanced cancer patients with solid

tumors (stage III-IV) and metastatic

patients where (re)-biopsy of tumor

tissue is not possible or desired

Key activities

Clinical advisory board

Development program underway

Early access program for research use

only LDT, expected 2H 2015

Lead oncology product

Highlights

Financial overview

$ Millions

Revenue*

$94M*** in cash and investments

Reduced cash burn by 66% from

$107M** in FY2013 to $37M** in

FY2014

Cash burn for Q4 was

approximately $7M**

Annual Cash Burn*

$ Millions

Note:

Revenue and cash burn exclude Sequenom Bioscience, a

discontinued operation. Amounts from continuing operations

are management’s estimates subject to change upon audit.

Preliminary, unaudited. Cash burn is cash used in operations, for

capital expenditures, and payments on term loans and capital

leases. Cash burn excludes the proceeds and payments from

the Illumina, ISIS and CUHK transactions in 2014.

***

Company received an additional $6M in January 2015 related to

Illumina settlement agreement bringing the total cash to

approximately $100M.

Metrics

2015 Commentary

2014

160M covered commercial lives

162K

accessioned

MaterniT21

PLUS

tests;

197K

total

accessioned

tests

revenues

approximately

$37M

New

Tier

CPT

code

applicable

for

MaterniT21

PLUS

NIPT

effective

January

Test

fees

and

royalties

are

expected

range

between

$6M

$14M

Expect

total

accessioned

tests

200K,

including

impact

patent

pool

licensees

Preliminary, unaudited.

Range

considers

uncertainty

number

Pool

Participants,

timing

implementing

NIPT

tests,

and

the

associated

timing

test

fees

and

royalties.

Range

considers

uncertainty

number

Pool

Participants,

timing

implementing

NIPT

tests,

and

the

associated

timing

test

fees

and

royalties, among other factors. Sequenom expects to have approximately $24M-$27M of non-cash expenses.

New Products

–

Sequenom Laboratories to launch 3 new laboratory-

developed tests

New Markets

–

Early access program for Liquid Biopsy RUO, 2H 2015

Operations

–

Total

cash

burn:

-$15M

+$15M

Corporate Goals 2015

CONTACT:

CAROLYN D. BEAVER, CFO

INVESTORRELATIONS@SEQUENOM.COM

WWW.SEQUENOM.COM

These laboratory-developed tests were developed and their performance characteristics determined by Sequenom Laboratories. They have not been cleared or approved by the U.S.

Food and Drug Administration (FDA). Although laboratory-developed tests to date have not been subject to U.S. FDA regulation, certification of the laboratory is required under CLIA

to ensure the quality and validity of the tests. This laboratory is accredited and certified to perform high complexity clinical laboratory testing.

Sequenom,

Inc.

All

rights

reserved.

Sequenom

HerediT™,

MaterniT21

PLUS,

RetnaGene™,

SensiGene™,

NextView™

and

VisibiliT™,

are

trademarks

Sequenom,

Inc.

All other trademarks are the property of their respective owners. The information herein is for informational purposes only and represents the current view of Sequenom, Inc. as of the

date of this presentation. Sequenom cannot guarantee the accuracy of any information provided after the date of this presentation. Sequenom makes no warranties, express, implied

or statutory, as to the information in this presentation.